Trial Profile
An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA (Isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Apr 2021
Price :
$35
*
At a glance
- Drugs Isotretinoin (Primary)
- Indications Nodulocystic acne
- Focus Therapeutic Use
- Sponsors Sun Pharmaceutical Industries
- 02 Nov 2018 Status changed from active, no longer recruiting to completed.
- 18 Apr 2017 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2017.
- 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.